Upacicalcet (sodium)
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Upacicalcet (sodium)
Description :
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM) . Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152) -induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD) . Upacicalcet sodium is useful for studying SHPT[1][2].Product Name Alternative :
SK-1403; AJT240; PLS240UNSPSC :
12352005Target :
CaSRType :
Reference compoundRelated Pathways :
GPCR/G ProteinApplications :
Metabolism-protein/nucleotide metabolismField of Research :
EndocrinologyAssay Protocol :
https://www.medchemexpress.com/upacicalcet-sodium.htmlPurity :
99.91Solubility :
DMSO : 100 mg/mL (ultrasonic)Smiles :
O=C(NC[C@H](N)C(O[Na])=O)NC1=CC(S(=O)(O)=O)=CC(Cl)=C1CMolecular Formula :
C11H13ClN3NaO6SMolecular Weight :
373.75References & Citations :
[1]Goto M, et al. Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo. Eur J Pharmacol. 2023 Oct 5;956:175936.|[2]Sato H, et al. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model. Bone. 2023 Feb;167:116613.Shipping Conditions :
Blue IceStorage Conditions :
-20°C (Powder, sealed storage, away from moisture)Scientific Category :
Reference compound1Clinical Information :
LaunchedCAS Number :
[2052969-18-1]
